-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $16

Benzinga·10/30/2026 11:40:40
Listen to the news
HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $38 to $16.